Neovacs

Neovacs FCF Yield

The Free Cash Flow Yield of Neovacs (ALNEV.PA) as of Oct 14, 2026 is -482,424.64 %. In the previous year, Free Cash Flow Yield was -277,575.36 % — a change of 73.80% (lower).

FCF Yield

-482,424.64 %

YoY

73.80%

Last updated:

Free Cash Flow Yield of Neovacs is 2024 -482,424.64 % . Free Cash Flow Yield of Neovacs was 2023 -277,575.36 % . It decreases by 73.80% lower compared to the previous year.

The Neovacs FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2017
-1.89 M EUR
Jan 1, 2018
-1.75 M EUR
Jan 1, 2019
-1.06 M EUR
Jan 1, 2020
-767,654.00 EUR
Jan 1, 2021
-1.34 M EUR
Jan 1, 2022
-603,682.83 EUR
Jan 1, 2023
-277,575.36 EUR
Jan 1, 2024
-482,424.64 EUR
The Neovacs FCF Yield history
YEARFCF YieldYoY
-482,424.64 %+73.80%
-277,575.36 %-54.02%
-603,682.83 %-55.10%
-1.34 M %+75.16%
-767,654.00 %-27.70%
-1.06 M %-39.16%
-1.75 M %-7.46%
-1.89 M %+29.48%
-1.46 M %+44.15%
-1.01 M %-4.54%
-1.06 M %—
Access this data via the Eulerpool API

Neovacs Stock analysis

What does Neovacs do? Neovacs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neovacs stock

Free Cash Flow Yield of Neovacs is -482,424.64 % in 2024.

Free Cash Flow Yield of Neovacs changed from -277,575.36 % to -482,424.64 %, representing a 73.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Neovacs since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Neovacs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Neovacs

All Key Metrics — Neovacs